Author:
Syed B M,Green A R,Paish E C,Soria D,Garibaldi J,Morgan L,Morgan D A L,Ellis I O,Cheung K L
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Abd El-Rehim D, Ball G, Pinder S, Rakha E, Paish C, Robertson J, Macmillan D, Blamey R, Ellis I (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116: 340–350
2. Abd El-Rehim D, Pinder S, Paish C, Bell J, Blamey R, Robertson J, Nicholson R, Ellis I (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203 (2): 661–671
3. Akhtar S, Allan S, Rodger A, Chetty U, Smyth J, Leonard R (1991) A 10-year experience of tamoxifen as primary-treatment of breast-cancer in 100 elderly and frail patients. Eur J Surg Oncol 17: 30–35
4. Aleskandarany M, Rakha E, Macmillan R, Powe D, Ellis I, Green A (2011) MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 127 (3): 591–599
5. Allan SG, Rodger A, Smyth JF, Leonard RC, Chetty U, Forrest AP (1985) Tamoxifen as primary treatment of breast cancer in elderly or frail patients: a practical management. Br Med J (Clin Res Ed) 290 (6465): 358